Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Loss $-0.36, vs. Street Est of $-0.32

11/10/2021 | 07:31am EST


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements..
AQ
01/14VYNE Therapeutics Inc. Announces Board Changes
CI
01/14Health Care Stocks Drop Premarket Friday
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
01/13Wall Street Set for Narrow Gains; US Wholesale Prices Rise Less Than Expected in Decemb..
MT
01/13Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS In..
PR
01/13Journey Medical Acquires Vyne Therapeutics' Molecule Stabilizing Technology Franchise
MT
01/13VYNE THERAPEUTICS : Divests Topical Minocycline Assets - Form 8-K
PU
01/13VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Completion of Acquisi..
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 16,6 M - -
Net income 2021 -69,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,51x
Yield 2021 -
Capitalization 36,8 M 36,8 M -
Capi. / Sales 2021 2,22x
Capi. / Sales 2022 4,85x
Nbr of Employees 106
Free-Float 92,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,69 $
Average target price 5,80 $
Spread / Average Target 744%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-32.64%37
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075